Jon Faiz Kayyem - 19 Nov 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Role
Director
Signature
/s/ Kelly Deck, as attorney-in-fact to Jon Faiz Kayyem
Issuer symbol
INBX
Transactions as of
19 Nov 2024
Net transactions value
+$1,523,620
Form type
4
Filing time
22 Nov 2024, 16:03:55 UTC
Previous filing
24 Jun 2024
Next filing
06 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INBX Common Stock Purchase $495,708 +34,843 +214% $14.23 51,093 19 Nov 2024 By Child A F1, F2
transaction INBX Common Stock Purchase $495,708 +34,843 +214% $14.23 51,093 19 Nov 2024 By Child B F1, F3
transaction INBX Common Stock Purchase $266,102 +18,750 +37% $14.19 69,843 20 Nov 2024 By Child A F2, F4
transaction INBX Common Stock Purchase $266,102 +18,750 +37% $14.19 69,843 20 Nov 2024 By Child B F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were purchased in multiple transactions at prices ranging from $14.09 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2 These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F3 These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F4 The shares were purchased in multiple transactions at prices ranging from $13.93 to $14.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.